Literature DB >> 11504497

Drug resistance in Cryptococcus neoformans.

John R. Perfect1, Gary M. Cox.   

Abstract

Cryptococcus neoformans has become a major opportunistic fungal pathogen worldwide. Successful treatment of invasive disease with this fungus has used amphotericin B, flucytosine and various azoles. However, treatment failures continue to occur for a variety of reasons including direct antifungal drug resistance. Issues and mechanisms for antifungal drug resistance in Cryptococcus neoformans are reviewed. Furthermore, approaches and strategies for prevention and treatment of antifungal drug resistance are identified and these include host immune modulation, dose optimization, prophylaxis/empirical regimens, improved drug delivery systems such as lipid preparations of amphotericin B, surgery, combination antifungal treatments and development of new antifungal agents. Copyright 1999 Harcourt Publishers Ltd.

Entities:  

Year:  1999        PMID： 11504497     DOI： 10.1054/drup.1999.0090

Source DB:  PubMed          Journal:  Drug Resist Updat        ISSN： 1368-7646            Impact factor:   18.500


  35 in total

Review 1.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

2.  G484S amino acid substitution in lanosterol 14-alpha demethylase (ERG11) is related to fluconazole resistance in a recurrent Cryptococcus neoformans clinical isolate.

Authors:  Laura Rodero; Emilia Mellado; A Carolina Rodriguez; Angela Salve; Liliana Guelfand; Pedro Cahn; Manuel Cuenca-Estrella; Graciela Davel; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

3.  An overview about the medical use of antifungals in Portugal in the last years.

Authors:  Maria Manuel da S Azevedo; Luisa Cruz; Cidália Pina-Vaz; Acácio Gonçalves-Rodrigues
Journal:  J Public Health Policy       Date:  2016-02-11       Impact factor: 2.222

Review 4.  Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.

Authors:  Leah E Cowen; William J Steinbach
Journal:  Eukaryot Cell       Date:  2008-03-28

5.  The Investigational Drug VT-1129 Is a Highly Potent Inhibitor of Cryptococcus Species CYP51 but Only Weakly Inhibits the Human Enzyme.

Authors:  Andrew G S Warrilow; Josie E Parker; Claire L Price; W David Nes; Edward P Garvey; William J Hoekstra; Robert J Schotzinger; Diane E Kelly; Steven L Kelly
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

6.  Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis.

Authors:  E Dannaoui; M Abdul; M Arpin; A Michel-Nguyen; M A Piens; A Favel; O Lortholary; F Dromer
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

7.  Multiple Phenotypic and Genotypic Artemisinin Sensitivity Evaluation of Malian Plasmodium falciparum Isolates.

Authors:  Karamoko Niaré; Lucie Paloque; Sandie Ménard; Pety Tor; Arba P Ramadani; Jean-Michel Augereau; Antoine Dara; Antoine Berry; Françoise Benoit-Vical; Ogobara K Doumbo
Journal:  Am J Trop Med Hyg       Date:  2018-02-08       Impact factor: 2.345

8.  Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine.

Authors:  A Espinel-Ingroff; A Chowdhary; M Cuenca-Estrella; A Fothergill; J Fuller; F Hagen; N Govender; J Guarro; E Johnson; C Lass-Flörl; S R Lockhart; M A Martins; J F Meis; M S C Melhem; L Ostrosky-Zeichner; T Pelaez; M A Pfaller; W A Schell; L Trilles; S Kidd; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

9.  Phospholipid-binding protein Cts1 controls septation and functions coordinately with calcineurin in Cryptococcus neoformans.

Authors:  Deborah S Fox; Gary M Cox; Joseph Heitman
Journal:  Eukaryot Cell       Date:  2003-10

10.  Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes.

Authors:  Edward Sionov; Hyeseung Lee; Yun C Chang; Kyung J Kwon-Chung
Journal:  PLoS Pathog       Date:  2010-04-01       Impact factor: 6.823
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.